This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Sun.Nov 27, 2022

article thumbnail

Answer of the Day for Nov 28, 2022

TheAnswerPage

NOVEMBER 27, 2022

Has any national drug administration approved a CBD-containing product for therapeutic use in conditions other than epilepsy? Yes. The oromucosal spray Sativex (nabiximols) is a cannabis extract that contains the principal cannabinoids delta-9-tetrahydrocannibinol (THC) and cannabidiol (CBD) in a 50:50 ratio, as well as specific minor cannabinoids and other non-cannabinoid components.

Nerve Pain 52
Nerve Pain Cannabinoids Epilepsy CBD 52
article thumbnail

Cerity Partners LLC Acquires New Position in Aurora Cannabis Inc.

Cannabis Law Report

NOVEMBER 27, 2022

Cerity Partners LLC acquired a new stake in Aurora Cannabis Inc. (NYSE:ACB – Get Rating) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 45,358 shares of the company’s stock, valued at approximately $60,000. Other hedge funds and other institutional investors have also […].

Cannabis 52
Cannabis 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 25,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2023